S&P 500   4,356.45
DOW   34,297.73
QQQ   345.11
S&P 500   4,356.45
DOW   34,297.73
QQQ   345.11
S&P 500   4,356.45
DOW   34,297.73
QQQ   345.11
S&P 500   4,356.45
DOW   34,297.73
QQQ   345.11

Biogen Stock Forecast, Price & News

$222.31
-2.38 (-1.06%)
(As of 01/25/2022 04:00 PM ET)
Add
Compare
Today's Range
$218.37
$224.91
50-Day Range
$220.52
$258.38
52-Week Range
$214.88
$468.55
Volume
1.51 million shs
Average Volume
2.06 million shs
Market Capitalization
$32.66 billion
P/E Ratio
21.75
Dividend Yield
N/A
Beta
0.44
30 days | 90 days | 365 days | Advanced Chart
Receive BIIB News and Ratings via Email

Sign-up to receive the latest news and ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter.


Biogen logo

About Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:BIIB
CUSIP
09062X10
Employees
9,100
Year Founded
1978

Sales & Book Value

Annual Sales
$13.44 billion
Cash Flow
$36.38 per share
Book Value
$69.44 per share

Profitability

Net Income
$4.00 billion
Pretax Margin
15.25%

Debt

Price-To-Earnings

Miscellaneous

Free Float
146,100,000
Market Cap
$32.66 billion
Optionable
Optionable

Company Calendar

Last Earnings
10/19/2021
Today
1/26/2022
Next Earnings (Confirmed)
2/03/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

2.17 out of 5 stars

Medical Sector

434th out of 1,416 stocks

Biological Products, Except Diagnostic Industry

65th out of 206 stocks

Analyst Opinion: 4.2Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












Biogen (NASDAQ:BIIB) Frequently Asked Questions

Is Biogen a buy right now?

31 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last twelve months. There are currently 16 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Biogen stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BIIB, but not buy additional shares or sell existing shares.
View analyst ratings for Biogen
or view top-rated stocks.

How has Biogen's stock price been impacted by Coronavirus (COVID-19)?

Biogen's stock was trading at $294.25 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, BIIB shares have decreased by 24.4% and is now trading at $222.31.
View which stocks have been most impacted by COVID-19
.

When is Biogen's next earnings date?

Biogen is scheduled to release its next quarterly earnings announcement on Thursday, February 3rd 2022.
View our earnings forecast for Biogen
.

How can I listen to Biogen's earnings call?

Biogen will be holding an earnings conference call on Thursday, February 3rd at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Biogen's earnings last quarter?

Biogen Inc. (NASDAQ:BIIB) announced its earnings results on Tuesday, October, 19th. The biotechnology company reported $4.77 earnings per share for the quarter, beating analysts' consensus estimates of $4.09 by $0.68. The biotechnology company had revenue of $2.78 billion for the quarter, compared to analyst estimates of $2.67 billion. Biogen had a net margin of 13.93% and a trailing twelve-month return on equity of 28.36%. Biogen's revenue was down 17.7% on a year-over-year basis. During the same period last year, the business posted $8.84 EPS.
View Biogen's earnings history
.

What guidance has Biogen issued on next quarter's earnings?

Biogen updated its FY 2021 earnings guidance on Wednesday, November, 3rd. The company provided EPS guidance of $18.850-$19.350 for the period, compared to the Thomson Reuters consensus EPS estimate of $18.610. The company issued revenue guidance of $10.80 billion-$10.90 billion, compared to the consensus revenue estimate of $10.76 billion.

What price target have analysts set for BIIB?

31 analysts have issued twelve-month price targets for Biogen's stock. Their forecasts range from $195.00 to $500.00. On average, they expect Biogen's share price to reach $306.52 in the next twelve months. This suggests a possible upside of 37.9% from the stock's current price.
View analysts' price targets for Biogen
or view top-rated stocks among Wall Street analysts.

Who are Biogen's key executives?

Biogen's management team includes the following people:
  • Michel Vounatsos, Chief Executive Officer & Director
  • Alphonse Galdes, EVP-Pharmaceutical Operations & Technology
  • Michael R. McDonnell, Chief Financial Officer & Executive Vice President
  • Mark Hernon, Chief Information Officer & Senior Vice President
  • Mahalakshmi Radhakrishnan, Chief Medical Officer & Group Senior VP

What is Michel Vounatsos' approval rating as Biogen's CEO?

186 employees have rated Biogen CEO Michel Vounatsos on Glassdoor.com. Michel Vounatsos has an approval rating of 86% among Biogen's employees.

What other stocks do shareholders of Biogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Amgen (AMGN), Walt Disney (DIS), Intel (INTC), Micron Technology (MU) and Boeing (BA).

What is Biogen's stock symbol?

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Who are Biogen's major shareholders?

Biogen's stock is owned by a variety of institutional and retail investors. Top institutional investors include Nordea Investment Management AB (0.31%), AustralianSuper Pty Ltd (0.13%), New York State Teachers Retirement System (0.12%), Railway Pension Investments Ltd (0.11%), Russell Investments Group Ltd. (0.07%) and Royal London Asset Management Ltd. (0.07%). Company insiders that own Biogen stock include Alfred Sandrock, Brian S Posner, Michel Vounatsos and Stephen A Sherwin.
View institutional ownership trends for Biogen
.

Which major investors are selling Biogen stock?

BIIB stock was sold by a variety of institutional investors in the last quarter, including Railway Pension Investments Ltd, M&G Investment Management Ltd., AustralianSuper Pty Ltd, IFP Advisors Inc, State of Alaska Department of Revenue, Wealthfront Advisers LLC, New York State Teachers Retirement System, and Gateway Investment Advisers LLC. Company insiders that have sold Biogen company stock in the last year include Alfred Sandrock, and Brian S Posner.
View insider buying and selling activity for Biogen
or view top insider-selling stocks.

Which major investors are buying Biogen stock?

BIIB stock was bought by a variety of institutional investors in the last quarter, including Cutler Group LP, XR Securities LLC, Sepio Capital LP, Exchange Traded Concepts LLC, Retirement Systems of Alabama, National Bank of Canada FI, Dixon Hubard Feinour & Brown Inc. VA, and Evergreen Wealth Solutions LLC.
View insider buying and selling activity for Biogen
or or view top insider-buying stocks.

How do I buy shares of Biogen?

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biogen's stock price today?

One share of BIIB stock can currently be purchased for approximately $222.31.

How much money does Biogen make?

Biogen has a market capitalization of $32.66 billion and generates $13.44 billion in revenue each year. The biotechnology company earns $4.00 billion in net income (profit) each year or $10.22 on an earnings per share basis.

How many employees does Biogen have?

Biogen employs 9,100 workers across the globe.

Does Biogen have any subsidiaries?

The following companies are subsidiares of Biogen: AliveGen, Biogen (Argentina) SRL, Biogen (Czech Republic) s.r.o., Biogen (Denmark) A/S, Biogen (Denmark) Manufacturing ApS, Biogen (Denmark) New Manufacturing ApS, Biogen (RTP) Realty LLC, Biogen (Singapore) Pte Ltd, Biogen Australia PTY Ltd, Biogen Austria GmbH, Biogen B.V., Biogen Belgium N.V./S.A., Biogen Biotechnology (Shanghai) Co. Ltd., Biogen Brasil Produtos Farmaceuticos LTDA, Biogen Canada Inc., Biogen Chesapeake LLC, Biogen Chile Spa, Biogen Colombia S.A.S., Biogen Finland OY, Biogen Foundation Inc., Biogen France S.A.S., Biogen GmbH, Biogen Holding APS, Biogen Holding I LLC, Biogen Holding II LLC, Biogen Hungary KFT, Biogen Idec (Ireland) Ltd., Biogen Idec Biotech India Pvt. Ltd., Biogen Idec Hong Kong Limited, Biogen Idec Ltd., Biogen Idec Research Ltd., Biogen Idec Uruguay SA, Biogen International GmbH, Biogen International Holding Limited, Biogen International Neuroscience GmbH, Biogen Italia SRL, Biogen Japan Ltd., Biogen Korea, Biogen Luxembourg Holding SARL, Biogen MA Inc., Biogen Management Services GmbH, Biogen Manufacturing Holding LLC, Biogen Mexico S. DE R.L. DE C.V., Biogen Mexico Servicios S. DE R.L. DE C.V., Biogen NZ Biopharma Ltd., Biogen Netherlands B.V., Biogen New Ventures Inc., Biogen Norway AS, Biogen Pharma farmacevtska in biotehnoloska druzba d.o.o, Biogen Poland Sp. z.o.o, Biogen Portugal Sociedade Farmaceutica Unipessoal Lda., Biogen Realty Corporation, Biogen Realty Limited Partnership, Biogen SRO Inc., Biogen Slovakia s.r.o., Biogen Spain S.L., Biogen Sweden AB, Biogen Swiss Investments GmbH, Biogen Swiss Manufacturing GmbH, Biogen Switzerland AG, Biogen Switzerland Holdings GmbH, Biogen Taiwan Limited, Biogen Therapeutics Inc., Biogen U.S. Corporation, Biogen U.S. Limited Partnership, Biogen U.S. Pacific LLC, Biogen U.S. West Corporation, Conforma Therapeutics, Conforma Therapeutics Corporation, Convergence Pharmaceuticals, Convergence Pharmaceuticals Holdings Ltd., Convergence Pharmaceuticals Ltd., Eidetica Biopharma GmbH, Fumapharm, Karyopharm Therapeutics, Nightstar Europa Limited, Nightstar Inc., Nightstar Limited, Nightstar Therapeutics, Nightstar Therapeutics Limited, Old Convergence Pharmaceuticals Ltd., Panion Ltd., Remedy Pharmaceuticals, Silver Acquisition Co. Ltd., Stromedix, Stromedix Inc., Syntonix Pharmaceuticals, Tungsten Bidco Limited, and Tysabri.

When was Biogen founded?

Biogen was founded in 1978.

What is Biogen's official website?

The official website for Biogen is www.biogen.com.

Where are Biogen's headquarters?

Biogen is headquartered at 225 BINNEY STREET, CAMBRIDGE MA, 02142.

How can I contact Biogen?

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at (617) 679-2000, via email at [email protected], or via fax at 617-679-2617.


This page was last updated on 1/26/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.